Prothena Corporation plc (PRTA) Stock Analysis
A live, multi-source view of Prothena Corporation plc (PRTA): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease.
Sector: Healthcare · Industry: Biotechnology · Ireland · 67 employees · prothena.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Prothena Corporation plc (PRTA) had a market capitalization of $504.1M (forward -6.5) and a beta of -0.33; the shares traded in a 52-week range of $7.73 – $11.80 (15.7% over the year).
- Market cap
- $504.1M
- Enterprise value
- $222.9M
- Forward P/E
- -6.5
- Price / book
- 1.77
- EPS (trailing)
- $-0.82
- EPS (forward)
- $-1.52
- Payout ratio
- 0.0%
- 52-week range
- $7.73 – $11.80
- 52-week change
- 15.7%
- Beta
- -0.33
- Average volume
- 511,055
- Shares outstanding
- 51.3M
- Short % of float
- 20.05%
- Profit margin
- -80.7%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-09
In RapidTradeView’s 2026-09-09 scan of the US universe, Prothena Corporation plc (PRTA) last closed at $9.54 (the last completed close before that scan).
Technicals at the scan: RSI 56 (neutral territory), price +2.7% versus its 20-day average, 20-day versus 50-day average spread +2.5%, MACD histogram 0.04.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 62/100.
Next scheduled company event: in 57 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of PRTA; corporate insiders filed 4 buys and 0 sells (1 filer, latest disclosure 2026-09-03). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: William P. Scully (4B/0S). Who is trading what
RapidTradeView pick record
PRTA has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Prothena Corporation plc (PRTA) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell PRTA.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.